Vanguard Capital Management
NTLA icon

Vanguard Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Vanguard Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102M Buy
6,028,586
+944,481
+19% +$13.2M ﹤0.01% 1543
2026
Q1 		$65.2M Buy
+5,084,105
New +$64.8M ﹤0.01% 1707

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's NTLA Position: Q2 2026 in Review

Vanguard Capital Management increased its Intellia Therapeutics (NTLA) stake by 19% in Q2 2026, buying an estimated $13.2M and bringing the position to 6,028,586 shares worth $102M. The position accounts for ﹤0.01% of the portfolio, ranked #1543.

Vanguard Capital Management first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. 325 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Vanguard Capital Management held 6,028,586 shares of Intellia Therapeutics worth $102M as of Q2 2026.
  • Vanguard Capital Management bought 944,481 Intellia Therapeutics shares in Q2 2026, an estimated $13.2M.
  • Intellia Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1543 holding.
  • Vanguard Capital Management first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 325 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.